Zhao Wen-He, Wang Shi-Fu, Ding Wei, Sheng Jian-Ming, Ma Zhi-Min, Teng Li-Song, Wang Min, Wu Fu-Sheng, Luo Bing
Department of Oncological Surgery, the First Affiliated Hospital of Medical College, Zhejiang University, Hangzhou 310003, Zhejiang Province, China.
World J Gastroenterol. 2006 Mar 7;12(9):1356-61. doi: 10.3748/wjg.v12.i9.1356.
To study the apoptosis induced by preoperative oral 5'-DFUR administration in gastric adenocarcinoma and its mechanism of action.
Sixty gastric cancer patients were divided randomly into three groups (20 each group) before operation: group one:5'-DFUR oral administration at the dose of 800-1200 mg/d for 3 - 5 d, group two: 500 mg 5-FU + 200 mg/d CF by venous drip for 3 - 5 d,group three (control group). One or two days after chemotherapy, the patients were operated. Fas/FasL,PD-ECGF and PCNA were examined by immunohistochemistry and apoptotic tumor cells were detected by in situ TUNEL method. Fifty-four patients received gastrectomy, including 12 palliative resections and 42 radical resections. Six patients were excluded. Finally 18 cases in 5'-DFUR group, 16 cases in CF+5-FU group, and 20 cases in control group were analyzed.
There was no significant difference in patient mean age, gender, white blood cell count, haematoglobin (HB),thromboplastin, perioperative complication incidence, radical or palliation resection, invasion depth (T), lymphonode involvement (N),metastasis (M) and TNM staging among the three groups. However,the PCNA index (PI) in 5'-DFUR group (40.51+/-12.62) and 5-FU+CF group (41.12+/-15.26) was significantly lower than that in control group (58.33+/-15.69) (F=9.083, P=0.000). The apoptotic index (AI) in 5'-DFUR group (14.39+/-9.49) and 5-FU+CF group (14.11+/-9.68)was significantly higher than that in control group (6.88+/-7.37) (F=4.409, P=0.017).The expression rates of Fas and FasL in group one and group three were 66.7% (12/18) and 50% (9/18), 43.8% (7/16) and 81.3% (13/16), 45.0% (9/20) and 85% (17/20), respectively. The expression rate of FasL in 5'-DFUR group was significantly lower than that in the other two groups (chi2=6.708, P=0.035). Meanwhile, the expression rate of PD-ECGF was significantly lower in 5'-DFUR group (4/18,28.6%) than in CF+5-FU group(9/16,56.3%)and control group (13/20,65.0%) (chi2=7.542, P=0.023). The frequency of Fas expression was significantly correlated with palliative or radical resection (chi2=7.651, P=0.006), invasion depth (chi2=8.927, P=0.003), lymphatic spread (chi2=4.488, P=0.034) and UICC stages (chi2=8.063, P=0.045) respectively. By the end of March 2005,45 patients were followed up. The 0.5-, 1-, 2-, 3-year survival rates were 96%,73%,60%,48%, respectively, which were related with T, N, M and Fas expression, but not with PD-ECGF and FasL expression.
Preoperative oral 5'-DFUR administration may induce apoptosis of gastric carcinoma cells and decrease tumor cell proliferation index,but cannot improve the prognosis of patients with gastric cancer.Down-regulation of FasL and PD-ECGF expression mediated by 5'-DFUR may be one of its anti-cancer mechanisms.Fas expression correlates with the progression of gastric carcinoma and may be an effective prognostic factor.
研究术前口服5'-脱氧氟尿苷(5'-DFUR)诱导胃腺癌细胞凋亡及其作用机制。
60例胃癌患者术前随机分为三组(每组20例):一组:口服5'-DFUR,剂量为800 - 1200mg/d,共3 - 5天;二组:静脉滴注500mg 5-氟尿嘧啶(5-FU)+200mg/d亚叶酸钙(CF),共3 - 5天;三组(对照组)。化疗后1或2天进行手术。采用免疫组织化学法检测Fas/FasL、血小板衍生内皮细胞生长因子(PD-ECGF)和增殖细胞核抗原(PCNA),原位末端脱氧核苷酸转移酶介导的缺口末端标记法(TUNEL法)检测凋亡肿瘤细胞。54例患者接受了胃切除术,其中姑息性切除12例,根治性切除42例。6例患者被排除。最终分析5'-DFUR组18例、CF+5-FU组16例和对照组20例。
三组患者的平均年龄、性别、白细胞计数、血红蛋白(HB)、凝血酶原、围手术期并发症发生率、根治性或姑息性切除、浸润深度(T)、淋巴结转移(N)、远处转移(M)及TNM分期差异均无统计学意义。然而,5'-DFUR组(40.51±12.62)和5-FU+CF组(41.12±15.26)的PCNA指数(PI)显著低于对照组(58.33±15.69)(F = 9.083,P = 0.000)。5'-DFUR组(14.39±9.49)和5-FU+CF组(14.11±9.68)的凋亡指数(AI)显著高于对照组(6.88±7.37)(F = 4.409,P = 0.017)。一组和三组Fas和FasL的表达率分别为66.7%(12/18)和50%(9/18)、43.8%(7/16)和81.3%(13/16)、45.0%(9/20)和85%(17/20)。5'-DFUR组FasL的表达率显著低于其他两组(χ2 = 6.708,P = 0.035)。同时,5'-DFUR组PD-ECGF的表达率(4/18,28.6%)显著低于CF+5-FU组(9/16,56.3%)和对照组(13/20,65.0%)(χ2 = 7.542,P = 0.023)。Fas表达频率与姑息性或根治性切除(χ2 = 7.651,P = 0.006)、浸润深度(χ2 = 8.927,P = 0.003)、淋巴转移(χ2 = 4.488,P = 0.034)及国际抗癌联盟(UICC)分期(χ2 = 8.063,P = 0.045)均显著相关。至2005年3月底,45例患者进行了随访。0.5年、1年、2年、3年生存率分别为96%、73%、60%、48%,其与T、N、M及Fas表达有关,但与PD-ECGF和FasL表达无关。
术前口服5'-DFUR可诱导胃癌细胞凋亡并降低肿瘤细胞增殖指数,但不能改善胃癌患者的预后。5'-DFUR介导的FasL和PD-ECGF表达下调可能是其抗癌机制之一。Fas表达与胃癌进展相关,可能是有效的预后因素。